|
|
Vaccine Detail
|
MERS-CoV pcDNA3.1-S1 DNA vaccine |
| Vaccine Information |
- Vaccine Name: MERS-CoV pcDNA3.1-S1 DNA vaccine
- Target Pathogen: MERS-CoV
- Target Disease: Middle East Respiratory Syndrome (MERS)
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: S from MERS-CoV (Chi et al., 2017)
- S from MERS-CoV
gene engineering:
- Type: DNA vaccine construction
- Description: Plasmid created containing first 735 amino acids of S from MERS-CoV (Chi et al., 2017)
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: DNA vaccine encoding the first 725 amino acids of S from MERS-CoV induces antigen-specific humoral and cellular immune responses in mice (Chi et al., 2017)
|
| Host Response |
|
Mouse Response
- Host Strain: Balb/c (Chi et al., 2017)
- Host age: 6-8 weeks (Chi et al., 2017)
- Host gender: Female (Chi et al., 2017)
- Vaccination Protocol: injected intramuscularly in the quadriceps muscle with 100 μg recombinant plasmid in 100 μL PBS on week 0, 3, 6 (Chi et al., 2017)
- Immune Response: Anti-antigen IgG response and strong neutralizing activity, production of IFN-γ, production of IL-2, IL-4, IL-10, increase in IFN-γ-producing CD4+ and CD8+ T cells. (Chi et al., 2017)
|
| References |
Chi et al., 2017: Chi H, Zheng X, Wang X, Wang C, Wang H, Gai W, Perlman S, Yang S, Zhao J, Xia X. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine. 2017; 35(16); 2069-2075. [PubMed: 28314561].
|
|
